Moderna, Inc. Common Stock (MRNA) — Analysis Summary
Moderna, Inc. Common Stock (MRNA) has a market cap of $57.00B with year-over-year revenue growth of -39.9%. Net margin stands at -145.2%. The stock trades at a P/E ratio of -18.1.
Key Takeaways
- Revenue changed -39.9% year-over-year
- Net margin of -145.2%
- P/E ratio of -18.1
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, MRNA posted revenue growth of -39.9% and trades at a P/E of -18.1.
Moderna, Inc. Common Stock (MRNA)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -149.0% — severe operating losses
Net margin at -141.4% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
4,700
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.